Thiazolidinediones

Thiazolidinediones and liver toxicity.

Thiazolidinediones or glitazones specifically target insulin resistance. They have proven efficacy for reducing plasma glucose levels of type 2 diabetic patients treated with diet alone, sulphonylureas, metformin or insulin. In addition, they may be associated to some improvement of cardiovascular risk profile. However, troglitazone, the first compound approved by the FDA in the US, proved to b...

Thiazolidinediones and bone fractures

The topic of increased risk of bone fracture associated with thiazolidinediones (TZD) treatment first drew international attention when a higher rate of fractures in women with diabetes treated with rosiglitazone was reported in the A Diabetes Outcome Program Trial (ADOPT). Subsequently, a number of clinical trials and observational studies addressing this issue have been reported and most of t...

Thiazolidinediones: a 2010 perspective.

A large number of cardiology clinical trials have mortality as an endpoint unless adequate surrogate endpoints are available. Although there are nine classes of agents used in the treatment of diabetes mellitus, none have shown a mortality benefit in clinical trials. The United Kingdom Prospective Diabetic Study was the first to suggest that metformin given for diabetes mellitus had a trend tow...

Antiatherogenic effects of thiazolidinediones?

Treatment of type 2 diabetes mellitus (DM) is directed at relieving symptoms of hyperglycemia and reducing the incidence of diabetes-associated pathologies. Complications of atherosclerosis, including myocardial infarction and stroke, are the most common causes of death in diabetic patients. Thiazolidinediones (TZDs) represent a relatively recent addition to the arsenal of pharmaceutical option...

Thiazolidinediones: do harms outweigh benefits?